Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials (Q57618049)

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Nanoparticle therapeutics: a personal perspective.

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Emerging nanopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Selective prostate cancer thermal ablation with laser activated gold nanoshells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Doxil®--the first FDA-approved nano-drug: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Stealth® liposomes: from theory to product

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Tumour-targeted nanomedicines: principles and practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Advantages of liposomal delivery systems for anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Taxol stabilizes microtubules in mouse fibroblast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Protein nanoparticles as drug carriers in clinical medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Rexin-G, a targeted genetic medicine for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Childhood acute lymphoblastic leukaemia and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Management and preparedness for infusion and hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Superparamagnetic iron oxide: pharmacokinetics and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Nanoparticles in medicine: therapeutic applications and developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Nano cancer therapy strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Theranostic applications of nanoparticles in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Nanoparticle delivery of cancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Challenges to effective cancer nanotheranostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681

Evidence that the L-Asparaginase Activity of Guinea Pig Serum is responsible for its Antilymphoma Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F629681